










Manuscript: ACR Appropriateness Criteria
® 
Local-Regional Therapy for Resectable 
Oropharyngeal Squamous Cell Carcinomas 
 
 
Expert Panel on Radiation Oncology–Head & Neck:  
Jonathan J. Beitler, MD, MBA
1
 
Harry Quon, MD, MS
 2
 
Christopher U. Jones, MD
3
  
Joseph K. Salama, MD
4
  
Paul M. Busse, MD, PhD
5
 
Jay S. Cooper, MD
6
 
Shlomo A. Koyfman, MD
7
 
John A. Ridge, MD, PhD
8
 
Nabil F. Saba, MD
9
  
Farzan Siddiqui, MD, PhD
10
 






Min Yao, MD, PhD
13
 
Sue S. Yom, MD, PhD
14 
 
                                                 
1
Principal Author, Emory University School of Medicine, Atlanta, Georgia.  
2
Co-author, Johns Hopkins University, Baltimore, Maryland.  
3
Co-author, Radiological Associates of Sacramento, Sacramento, California.  
4
Panel Vice-chair, Duke University Medical Center, Durham, North Carolina.  
5
Massachusetts General Hospital, Boston, Massachusetts.  
6
Maimonides Cancer Center, Brooklyn, New York.  
7
Cleveland Clinic Foundation, Cleveland, Ohio.  
8
Fox Chase Cancer Center, Philadelphia, Pennsylvania, American College of Surgeons.  
9
Emory University, Atlanta, Georgia, American Society of Clinical Oncology.  
10
Henry Ford Hospital, Detroit, Michigan.  
11
Montefiore Medical Center, Bronx, New York, American College of Surgeons.  
12
University of Michigan, Ann Arbor, Michigan, American Society of Clinical Oncology.  
13
University Hospital Case Medical Center, Cleveland, Ohio.
  
14
Panel Chair, University of California San Francisco, San Francisco, California. 
Page 1 of 34 Head & Neck
This is the author manuscript accepted for publication and has undergone full peer review but has not been through the
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and
the Version record. Please cite this article as doi:10.1002/hed.24447.










The American College of Radiology seeks and encourages collaboration with other organizations on the 
development of the ACR Appropriateness Criteria through society representation on expert panels. 
Participation by representatives from collaborating societies on the expert panel does not necessarily 
imply individual or society endorsement of the final document. 
 
Conflict of Interest:  
Sue S. Yom, MD, PhD- “Genentech, Inc. - Research support (Dr. Yom is Principal Investigator of a 
supported clinical trial)” 
Christopher U. Jones, MD- “Bristol Myers Squibb - Role: Speaking and Teaching.” 
 
Corresponding Author:  
Jonathan J. Beitler, MD, MBA 
Attn: Department of Radiation Oncology  
Emory University School of Medicine  
550 Peachtree Street, NE 
Atlanta, GA  30308  
Email: jjbeitl@emory.edu 
 




Background: There are no level I studies to guide treatment for resectable oropharyngeal squamous cell 
carcinoma (OPSCC). Treatment toxicities influence management recommendations. Ongoing 
investigations are examining de-intensified treatments for HPV-associated OPSCC. 
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Methods: The Appropriateness Criteria
®
 panel, using modified Delphi methodology, produced a 
literature summary, an assessment of treatment recommendations and cases to illustrate their use. 
  
Results: A multidisciplinary team produces optimum results. Based on HPV status, smoking history, and 
staging, patients are divided into groups at low, intermediate, and high risk of death. In the future, 
treatment recommendations may be influenced by HPV status, which has changed the epidemiology of 
OPSCC. 
  
Conclusions: T1-T2N0M0 resectable OPSCC can be treated with surgery or radiation without 
chemotherapy. T1-2N1-2aM0 patients can receive radiation, chemoradiation, or transoral surgery with 
neck dissection (TORS-ND) and appropriate adjuvant therapy. T1-2N2b-3M0 patients should receive 
chemoradiation or TORS-ND and appropriate adjuvant therapy. Concurrent chemoradiation is preferred 
for T3-4 disease. 
 
Keywords –TBC 
Oropharyngeal Cancer, HPV, Tonsil Cancer, Base of Tongue Cancer, TORS 
 
Summary of Literature Review 
Introduction/Background 
The treatment options for resectable oropharyngeal (OP) carcinomas are diverse and include surgery, 
with or without postoperative radiation therapy (PORT)/chemoradiotherapy (based on pathologic 
findings and patient factors), or definitive radiation therapy/chemoradiotherapy with or without adjuvant 
surgery (based on post-treatment imaging or biopsy findings). There is no level 1 evidence comparing 
definitive surgery with definitive chemoradiation, so comparing survival, local regional control, 
function, or quality of life between surgical and nonsurgical therapies objectively has been difficult. 
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Prior to the initiation of treatment, all patients with oropharynx cancer should be evaluated by a 
multidisciplinary treatment team that includes a head and neck surgical oncologist. Only the surgeon can 
decide if the individual cancer can appropriately be treated by resection (by either transoral or 
transcervical techniques). Whether a particular oropharynx cancer can be removed with adequate 
postoperative form and function will depend upon the head and neck surgeon, the reconstructive team, 
adjunctive services (such as speech and swallowing therapy), the patient’s ability to participate in 
rehabilitation, and the need for adjuvant therapy. 
Common indications of unresectability of OP squamous cell carcinoma include involvement of the 
pterygoid muscles with severe trismus, pterygopalatine fossa involvement with cranial neuropathy, gross 
extension of tumor to the skull base (including erosion of the pterygoid plates or sphenoid bone), deep 
extension to the eustachian tube and lateral nasopharyngeal wall, and direct invasion or encasement of 
the internal or common carotid artery with radiographic evaluation suggesting disease involving ≥270° 
of the vessel circumference [1]. For purposes of this monograph, all other OP squamous cell carcinomas 
(including those of the base of the tongue that can be removed without concomitant total laryngectomy) 
are considered “resectable.” 
When deciding on the optimal treatment for a given patient, the treating team must consider the relative 
oncologic efficacy of various nonsurgical and surgical techniques, as well as preservation of appearance, 
swallowing, and speech function. For nonsurgical approaches, various treatment-intensification 
strategies have demonstrated increased success in local-regional disease control rates but at the cost of 
an increased risk of late swallowing dysfunction [2-4] with quantifiable impact on quality-of-life 
measures [5] (see Variant 1). 
Treatment selection is further influenced by the recent dominance of positive human papillomavirus 
(HPV)–related cancers within the oropharynx. HPV-related cancers are typically characterized by a 
younger patient population and a more favorable prognosis, as defined by superior local regional control 
and survival rates [6]. It is clear that amongst HPV-related OP carcinomas there is clinically significant 
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heterogeneity, defined by clinical factors such as tobacco exposure or tumor-node-metastasis stage. 
Regardless, this changing epidemiologic profile, compared to the prior profile associated with tobacco 
and ethanol abuse, has led to a reevaluation of successful treatment strategies and has provided the 
impetus to evaluate various treatment deintensification strategies, including radiation therapy dose de-
escalation protocols, elimination of chemotherapy, and reintroduction of surgery in an effort to limit the 
toxicities of the other 2 modalities. The impact of the clinical factors remains the subject of 
investigations and represents important stratification considerations in optimizing future 
deintensification strategies. 
Therapeutic Implications of Oropharyngeal Carcinomas in Human Papillomavirus–Positive 
Patients 
Population-based reports [7], retrospective reports [8-15], and clinical trials [16-21] analyzed with post 
hoc stratification based on the HPV status and at least 1 prospective trial [22] confirm that patients with 
HPV-positive OP carcinomas have significantly improved results after treatment. Most of these trials 
reported the results of patients treated with concurrent chemoradiotherapy. However, this does not 
guarantee that the favorable prognosis is due to increased radiation and chemotherapy sensitivity. 
Several studies have reported that HPV-positive patients treated with surgery with or without PORT had 
significantly improved survival compared to HPV-negative patients with OP carcinomas [9,11,13], 
suggesting improved prognosis may be treatment independent (see Variant 2). 
Complicating how OP carcinomas in HPV-positive patients should be treated is the recognition that a 
subgroup of these patients has an intermediate-level survival advantage compared to HPV-negative 
patients with OP carcinomas [13]. It is clear that a significant history of tobacco exposure consistently 
and adversely affects survival [15,19,23,24]. Advanced-clinical-stage HPV-positive OP carcinoma is 
associated with an inferior survival. This includes T4 tumors [25] and advanced nodal status, defined 





) 0129 used N2b-N3 nodal classification to “upstage” HPV-positive patients into the 
intermediate risk group [26], and a retrospective subgroup analysis of RTOG 9003 and 0129 used N0-1 
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versus N2-3 [19] to separate groups, although the Princess Margaret series suggested that N3 disease 
and patients with N2c disease not treated with chemotherapy are at higher risk for distant metastases 
[25]. Overall, when compared to the HPV status, the influence of N-stage can have less prognostic 
influence and potentially less therapeutic implications than what holds true for HPV-negative patients 
with OP carcinomas [9,11,14]. However, the specific finding of extracapsular extension (ECE) does 
appear to continue to affect survival [11], although further investigation continues and the definition of 
ECE is also evolving. These risk classifications require further validation but are likely to be important 
in identifying patients who may be suitable for treatment deintensification strategies. Alterations to 
standard therapeutic recommendations cannot yet be recommended (see Variant 3). 
Despite the continued debates, for the favorable HPV cohort in which mature 3-year disease-free 
survival rates on the order of ≥80% can be achieved [26], there is increasing emphasis on reducing the 
risk of late treatment complications, especially the risk of swallowing dysfunction. How this can be 
achieved is unclear at this time, but emphasis on radiation therapy dose reduction and alternative 
concurrent targeted therapy, chemotherapy regimens and schedules, or even elimination of 
chemotherapy are all under active consideration. Definitive transoral surgery may reduce or eliminate 
the need for radiation and/or chemotherapy for some patients. These efforts are based on the finding that 
the risk of late swallowing dysfunction and percutaneous endoscopic gastrostomy dependency have been 
shown to be independently affected by concurrent chemotherapy [2,3]. At this time, no level 1 evidence 
exists to favor any of these approaches. 
For the intermediate-risk HPV cohort, disease-free survival rates on the order of 55%–65% can be 
expected using current treatment strategies [13,15,19,26], suggesting a need for further judicious 
treatment intensification balanced against the possibility of long-term treatment complications. For the 
HPV-negative cohort, for whom survival rates of ≤50% can be expected when treated with standard 
concurrent chemoradiation, further investigational approaches are warranted. These can include further 
nonsurgical treatment intensification or a reevaluation of new transoral surgical techniques that carry 
less risk of swallowing complications [27-29] (see Variant 4). 
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Optimal Radiation Therapy Treatment Intensification 
Several strategies using radiation therapy intensification have yielded evidence demonstrating that 
improvements in local-regional disease control translate into survival gains. These include the 
incorporation of interstitial brachytherapy techniques, altered fractionated radiation therapy, and 
intensity-modulated radiation therapy (IMRT) with simultaneous in-field boost (SIB). 
The study of brachytherapy techniques has been limited to institutional experiences [30-34], and their 
relative oncologic efficacy compared to external beam radiation therapy techniques is completely 
untested. The generalizability of the results of these techniques is limited by the high level of skill and 
experience required for administering this treatment properly. The attraction of brachytherapy lies in the 
dosimetric advantages it confers both to the tumor and to the swallowing organs considered at risk for 
radiation injury. There is some controversy as to whether brachytherapy does [31,32] or does not [34] 
reduce the risk of late swallowing complications. 
Meta-analyses have demonstrated that altered fractionation schedules can translate into survival gains 
[35,36]. RTOG study 9003 demonstrated that in patients with locoregionally advanced head and neck 
cancer censored at 5 years, hyperfractionation showed a statistically significant improvement in survival 
[37] when compared to conventionally fractionated radiation therapy. However, using all information, 
both hyperfractionation and the concomitant boost arms decreased local-regional failure, compared to 
standard fractionation alone, by 19% (P=0.08 for both). Functionally, those treated with 
hyperfractionation had better outcomes, with only 4.8% of disease-free patients at 5 years having 
feeding tubes, versus 13.0% of concomitant-boost patients. 
These original fractionation studies predated the use of IMRT. It is reasonable to extrapolate a similar 
tumor control benefit for altered fractionation while using IMRT. However, any increased corresponding 
toxicity might theoretically be mitigated because the volume of normal tissue subjected to altered 
fractionation should be much smaller with IMRT than with conventional 3-D techniques. 
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More recently, the use of IMRT has facilitated the ability to prescribe a SIB, offering the ability to 
achieve highly conformal dose intensification. It remains to be determined if this prescription technique 
is equivalent to the delayed concomitant boost-accelerated fractionation schedule [38]. The only phase I 
trial conducted for SIB-IMRT enrolled 20 patients and demonstrated that a maximum tolerated dose 
occurred at 2.36 Gy delivered over 30 fractions to a total dose of 70.8 Gy. The final conclusion, based 
on acute toxicity evaluation, was that 2.27 Gy over 30 daily fractions was deemed to be safe; however, 6 
of 12 (11 of 12 OP carcinomas) were reported to have late toxicities, with 4 of 6 experiencing 
swallowing dysfunction [39]. Despite the recent increase in the use of IMRT for reasons of dose 
escalation and dosimetrically-based normal-tissue sparing [40], with some exceptions [41,42], the 
published experience for IMRT remains largely composed of retrospective institutional reports 
reflecting heterogeneous prescription and treatment-planning approaches [43,44]. Institutional 
retrospective reports [43,45] and comparative phase III studies [46-48] support the role of IMRT for 
parotid-sparing indications. Conventional 3-D conformal radiation therapy delivered by opposed lateral 
ports remains an acceptable alternative, but the weight of the evidence indicates that it does not offer the 
quality-of-life advantages seen with IMRT. The optimal prescription dose remains undefined, although 
most regimens attempt to mimic dose-fractionation patterns prescribed with conventional techniques or 
follow established institutional experiences. Procedures for cross-sectional anatomically based target 
definition and dose prescription have become critically important in the era of highly conformal 
radiation techniques. Close monitoring of IMRT outcomes in routine practice or referral to centers with 
expertise has been recommended, given the significant learning curve associated with the application of 
highly conformal irradiation to the head and neck [49,50] and the significant impact that appropriate 
treatment planning techniques can have on outcomes [51]. 
Optimal Concurrent Chemotherapy 
A meta-analysis [52] and multiple phase III trials [53,54] support the contention that platinum-based 
chemoradiation improves survival as compared to standard radiation alone. These experiences largely 
reflect but are not limited to the use of bolus dose schedules of cisplatin dose schedules typically at 100 
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. It is unclear if doublet regimens such as cisplatin or carboplatin in combination with 5-
fluorouracil (5-FU) produce survival gains comparable or superior to cisplatin alone [55]. Alternative 
regimens have gained recent attention because efforts are underway to develop risk-adapted therapies 
for low-risk HPV-associated OP carcinomas and for the elderly population, where the risk of late 
swallowing toxicities is of increased concern. Meta-analysis has demonstrated that with increasing 
patient age, treatment intensification with concurrent chemotherapy [52] (and altered fractionation [36]) 
provides less survival benefit and no significant benefit for patients over the age of 70. In addition, 
RTOG analyses show that advancing age is an independent risk factor for late swallowing toxicity when 
patients are treated with chemoradiation [4] (see Variant 5). 
Weekly dosing of cisplatin has been favored by some in the hope that the regimen is as effective but 
better tolerated than the traditional bolus cisplatin schedule of 100 mg/m
2
 every 3 weeks. However, an 
Intergroup randomized trial of 307 eligible patients comparing 20 mg/m
2
 of cisplatin with radiation to 
the same radiation therapy alone demonstrated no improvement in overall survival or freedom from 
failure, suggesting that 20 mg/m
2
 (weekly) was too low a dose. Unfortunately, low-dose cisplatin was 
still hazardous; he study revealed an increased risk of late larynx and esophageal toxicities with weekly 
cisplatin at 20 mg/m
2
 [56]. In the face of recognized toxicity, institutional practices favoring a weekly 
schedule have typically favored doses of ≥30 mg/m
2
. This is supported by data from nasopharyngeal 
carcinoma, where in endemic areas phase III studies of weekly cisplatin at 30–40 mg/m
2
 demonstrated 
significantly improved survival rates compared to radiation therapy alone [57,58]. The ability to 
generalize findings from nasopharyngeal cancer to OP carcinoma is unclear due to the different 
behaviors of carcinomas between these anatomic sites. A retrospective report of 50 patients, mostly with 
advanced laryngeal cancer, compared administration of bolus cisplatin at 100 mg/m
2
 every 3 weeks in 
younger patients with more favorable performance status (PS) to a schedule of weekly cisplatin at 40 
mg/m
2
 given to older patients with less favorable PS [59], combined with conventionally fractionated 
radiation therapy to 70 Gy. At short-term follow-up, local-regional disease control rates were 
comparable, but the follow-up was too short to make this conclusion anything but a working hypothesis. 
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Several small retrospective comparative reports using a range of weekly cisplatin doses from 20 mg/m
2
 
(in combination with 5-FU) to 40 mg/m
2 
versus bolus cisplatin at 80–100 mg/m
2
 have demonstrated 
more chemotherapy omissions and delays with use of the bolus high-dose schedule, raising concerns 
about the ability to achieve adequate dose intensity [60,61]. Several other institutional reports have 
described their results with weekly cisplatin at 40 mg/m
2
 [62,63] and 30 mg/m
2
 [64]. Overall, these 
results suggest comparable efficacy at 30–40 mg/m
2
, with a potentially more favorable acute toxicity 
profile with weekly cisplatin; but hematologic toxicities may still be limiting at a weekly dose of 40 
mg/m
2
 [63]. Despite these investigations, it is important to note that the most widely accepted standard 
of care, supported by level 1 evidence, remains the bolus cisplatin schedule. 
Concurrent Chemotherapy and Altered Fractionation 
For locally advanced cancers with poor prognosis, expert opinion has favored the use of concurrent 
chemotherapy with conventionally fractionated radiation over altered-fractionated radiation alone due to 
the consistent survival gains seen in individual phase III trials of chemoradiation. In GORTEC 99-02, 
concurrent chemotherapy with conventionally fractionated radiation showed improved 3-year 
progression-free survival (PFS) over accelerated radiation alone (hazard ratio [HR], 0.82; P=0.041) [65]. 
Concurrent chemotherapy may also potentially decrease the risk of distant relapse in advanced N2b-3 
neck disease [66]. A large retrospective analysis further supports the potential impact of concurrent 
chemotherapy on the risk of distant metastases in HPV-associated OP carcinoma patients with advanced 
N2b-N2c neck disease [25]. 
Altered fractionated radiation therapy schedules have also been studied in combination with concurrent 
chemotherapy [67] (see Variant 6). Updated results from a German multicenter trial demonstrated 
improved local-regional control rates and overall survival with the addition of concurrent carboplatin 
and 5-FU to an accelerated fractionation schedule (using a delayed concomitant boost) in the treatment 
of stage III/IV OP and hypopharyngeal carcinomas [68]. In contrast, accelerating the radiation therapy 
while using concurrent chemotherapy does not seem to confer an additional survival benefit. RTOG 
0129 demonstrated no significant improvement in 5-year overall survival (HR, 0.90; P=0.18) with the 
Page 10 of 34
John Wiley & Sons, Inc.
Head & Neck










use of a concomitant boost schedule and 2 cycles of concurrent bolus cisplatin when compared to a 
standard daily fractionated schedule with 3 cisplatin cycles. One conclusion generated by these results 
was that the beneficial effects of acceleration facilitated the omission of the third cycle of cisplatin. 
Similar findings were seen in GORTEC 99-02 [65], with no difference in PFS seen between accelerated 
radiation combined with 2 cycles of carboplatin and 5-FU versus conventional radiation and 3 cycles of 
chemotherapy, although acute mucosal toxicity appeared increased with the accelerated chemoradiation. 
It should be noted that these trials, similar to the radiation-alone trials, predated the use of IMRT. 
The Role of Ce uximab 
The use of weekly cetuximab, an epidermal growth factor receptor inhibitor, is another emerging 
radiosensitizing strategy. Mature results now confirm that superior local-regional disease control and 
survival rates are seen with the addition of concurrent cetuximab to radiation [69]. In the initial analysis, 
it was suggested that the greatest activity may occur for OP carcinomas [70], which represented the 
majority of cancers in the trial. In both arms, 75% of the patients were treated with either accelerated or 
hyperfractionation. The hypothesis that the combination of cetuximab and conventional radiation would 
be equally efficacious as schedules that use altered fractionation has not been tested. In the initial 
analysis, the opposite was suggested, as the combination of cetuximab with an altered fractionation 
schedule appeared to produce higher efficacy than when adding it to a conventional schedule [69]. 
How cetuximab directly compares to cisplatin as a radiosensitizer is currently unknown, but RTOG 
1016 (which has completed accrual) addressed the issue in HPV-positive patients with final results 
pending. RTOG 0522 evaluated the relative efficacy of accelerated fractionation radiation therapy in 
combination with either cisplatin or cisplatin and cetuximab [71]. Ang et al [71] reported that with a 
median follow-up of 3.8 years, both PFS and overall survival were not significantly improved with the 
addition of cetuximab, including a cohort of p16 positive tumors. However, increased acute toxicities, 
including mucositis, were observed (including increased radiation therapy interruptions) with the 
addition of concurrent cetuximab. Thus, use of concurrent cetuximab in combination with concurrent 
platinum chemoradiation cannot be recommended. 
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A randomized phase II trial of concurrent chemoradiation plus cetuximab in the postoperative setting 
has recently been reported [72]. Patients with high-risk squamous cell cancer were randomized to 





/wk). The docetaxel arm had a 13% 2-year distant failure rate, compared to a 25% 
2-year distant failure rate for cisplatin. This is being followed up with a phase III trial. 
Role for Induction Chemotherapy 
The addition of docetaxel [73-75] or paclitaxel [76] to the traditional cisplatin and 5-FU (PF) induction 
backbone in several phase III trials has improved survival. A significant motivation to employ induction 
chemotherapy was the hope that it might have an impact on the distant relapse rate, which becomes 
more relevant as local-regional disease control rates improve. Meta-analysis confirms that the addition 
of a taxane to cisplatin and 5-FU does significantly reduce the risk of distant metastasis (P=0.009), PFS 
(P<.001), and overall survival (P<0.001) [77]. Local-regional failure was also significantly reduced 
(P=0.007), though it is difficult to determine how much the induction chemotherapy is contributing to 
this endpoint, given the heterogeneity of the 5 randomized trials evaluated. In 2 phase III trials, 21%–
23% of patients who began with induction docetaxel + PF were not able to receive the subsequent 
planned chemoradiation [73,74,78]. 
To date, 4 randomized trials comparing induction chemoradiation to concurrent chemoradiation alone 
have been reported. Two closed early due to poor accrual rates. No significant survival differences were 
identified [79,80]. In the PARADIGM trial, unplanned subgroup analysis demonstrated a nonsignificant 
trend to superior PFS in patients with OP carcinomas who were treated with concurrent 
chemoradiotherapy alone compared to the OP carcinoma cohort receiving induction chemotherapy. HPV 
status was not evaluated in this trial. Thus, it is not clear to what extent the induction chemotherapy is 
contributing beyond the impact of concurrent chemoradiotherapy though it is clear that toxicities are 
increased [80]. In the DeCIDE trial, enrollment was limited to patients with N2-N3 disease with no 
significant improvement in distant failure-free survival, recurrence-free survival, or overall survival 
[79]. Hitt et al [81] reported the results of a 3-arm phase III trial of induction docetaxel + PF for 3 cycles 
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followed by concurrent cisplatin (bolus scheduled) chemoradiotherapy, induction PF for 3 cycles 
followed by concurrent cisplatin chemoradiotherapy and concurrent cisplatin-chemoradiotherapy in 439 
patients with unresectable head and neck squamous cell carcinoma (HNSCC) (43% with OP 
carcinomas). With a median follow-up of 23.8 (0.4–86.3) months, no significant differences were seen 
in the primary endpoint of PFS and time to treatment failure. A randomized phase II trial of patients 
with unresectable stage III/IV HNSCC including the oropharynx conducted by Italian investigators 
demonstrated superior complete response rates (primary endpoint), with a nonsignificant trend of 
improved progression-free and overall survival with the combination of induction chemotherapy 
followed by concurrent chemoradiotherapy (cisplatin and 5-FU), compared to concurrent 
chemoradiotherapy alone [82]. Unfortunately, the concurrent chemotherapy was weak and nonstandard 
[55]. 
Based on the evidence to date, the administration of induction chemotherapy combining a taxane with 
the PF doublet cannot be routinely recommended. Whether the activity seen with induction docetaxel + 
PF benefits high-risk cohorts of patients, such as those with a significant history of tobacco exposure, 
HPV-positive carcinoma, or HPV-negative carcinoma, is unclear and the subject of clinical trials. 
From a technical perspective, the impact of induction chemotherapy on highly conformal radiation 
therapy treatment planning can be significant. Major unsettled issues include the optimal number of 
chemotherapy cycles (as it impacts the time to start the radiation therapy); the optimal target volume 
definition, including whether or not the postchemotherapy volume can be treated and to what prescribed 
dose; and whether or not the treatment-planning computed tomography imaging should be done before 
or after the induction chemotherapy, due to potential dosimetric effects in changes in the neck contour 
with response to therapy (see Variant 7). 
In summary, induction chemotherapy in resectable OP carcinomas remains investigational, and its use 
should be restricted to selected patients at this time, preferably those treated on a clinical trial. Further 
intensification of induction regimens and novel multiagent or targeted agent combinations for either the 
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induction or concurrent phase are being explored. Trials have also been initiated using less demanding 
strategies following induction; in some cases, no concurrent systemic therapy is given, or a targeted 
therapy can be given concurrently after the induction program. These approaches are considered strictly 
investigational. 
Role of Organ-Preserving Surgery 
Transoral techniques offer the potential for organ-preserving surgical therapy, with retrospective and 
prospective reports showing less morbidity, with similar local control rates comparable to the 
experiences seen in radiation therapy series [27-29,83-86]. These techniques are preferred to traditional 
open surgical approaches because swallowing complication rates appear lower, with permanent 
gastrostomy tube rates ranging from 0%–3.9% [27-29]. As with the radiation therapy-based approaches, 
these reports have not evaluated speech and swallowing function prospectively, but they reflect less-
invasive approaches to exposure of the primary tumor that would otherwise have contributed to 
swallowing complications in the past. These methods remain limited to institutions with expertise in the 
techniques, and hence their generalizability has not been established. Transoral results are under active 
investigation (HPV-positive: ECOG 3311, NCT01898494) and the number of surgeons with 
demonstrated expertise is rising rapidly. There are no randomized trials directly comparing surgical and 
nonsurgical approaches. It has been hypothesized that, given the poor survival rates seen in HPV-
negative patients with OP carcinomas treated with radiation therapy as the primary modality, surgical 
resection might be of benefit [8]; but once again, strong evidence to support this contention is lacking. 
Indications for postoperative adjuvant radiation therapy [87] or chemoradiotherapy [88,89] have not 
been differentiated by HPV status, and this is another area with a wealth of theories but no convincing 
data.  
Role of Nonsurgical Deintensification Therapy 
There is a low-risk cohort of patients with HPV-associated OP carcinomas that has a favorable 
prognosis with current treatment but is also at risk for significant late treatment-related toxicities, 
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including swallowing dysfunction, that can impair quality of life. Defining this low-risk cohort is an area 
of investigation, along with treatment strategies intending to ameliorate current concurrent 
chemoradiotherapy toxicity. These include 1) the substitution of potentially more-selective 
radiosensitizers, such as cetuximab (the subject of the recently closed-to-accrual RTOG 1016, with no 
results available at this time); 2) de-escalation trials, including several ongoing institutional studies that 
are reducing the total radiation therapy dose with or without concurrent chemotherapy, as well as the 
national study in this vein, NRG-HN002; or 3) radiation therapy de-escalation based on responses 
observed following induction chemotherapy. One of the earliest trials to investigate the role of 
deintensification employing induction chemotherapy to identify a favorable cohort of HPV-associated 
OP carcinomas was E1308. Preliminary results of this phase II trial demonstrate that acute toxicities 
appear to be reduced, with no mature oncologic results available [90]. Treatment deintensification of 
HPV-associated OP carcinomas cannot be recommended outside of a clinical trial. 
Summary of Recommendations 
• Despite a smoking history, T1-2 N0 M0 resectable lateral OP cancer should be treated with either 
definitive surgery or definitive radiation, without any systemic agent. 
• A patient with T1-2 N1-2a M0 resectable OP cancer who is HPV-positive and a nonsmoker can be 
treated with definitive radiation alone, concurrent chemoradiation, or transoral surgery/neck 
dissection and appropriate adjuvant therapy. 
• A patient with T1-2 N2b-3 M0 resectable OP cancer who is HPV-positive and a nonsmoker is best 
treated with concurrent external radiation and cisplatin or transoral surgery, neck dissection, and 
appropriate adjuvant therapy. 
• A patient with T1-2 N1-2a M0 resectable OP cancer, either HPV-positive or HPV-negative, with a 
significant smoking history can be treated with definitive radiation alone, concurrent chemoradiation, 
or transoral surgery/neck dissection and appropriate adjuvant therapy. 
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• A patient with T1-2 N2b-3 M0 resectable OP cancer, either HPV-positive or HPV-negative, with a 
significant smoking history should receive concurrent chemoradiation or transoral surgery/neck 
dissection and appropriate adjuvant therapy. 
• Patients with resectable T3-4 N0-2a M0 OP cancer should preferentially receive concurrent external 
radiation and cisplatin. 
• Patients with resectable T3-4 N2b-3 M0 OP cancer should preferentially receive concurrent external 
radiation and cisplatin. 
Summary of Evidence 
Of the 90 references cited in the ACR Appropriateness Criteria® Local-Regional Therapy for 
Resectable Oropharyngeal Squamous Cell Carcinomas document, all of them are categorized as 
therapeutic references including 42 well designed studies, 29 good quality studies, and 2 quality studies 
that may have design limitations. There are 17 reference/references that may not be useful as primary 
evidence. 
The 90 references cited in the ACR Appropriateness Criteria® Local-Regional Therapy for Resectable 
Oropharyngeal Squamous Cell Carcinomas document were published between 1993-2014.  
While there are references that report on studies with design limitations, 71 well designed or good 
quality studies provide good evidence. 
Supporting Documents 
For additional information on the Appropriateness Criteria methodology and other supporting 
documents go to www.acr.org/ac. 
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Tables: ACR Appropriateness Criteria
® 
Local-Regional Therapy for  Resectable 
Oropharyngeal Squamous Cell Carcinomas 
 
Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 1: T1-2 N0 M0. 45-year-old man with a 20 pack/year smoking history. 
Treatment Rating Comments 
Conventional fractionated external beam 
radiation therapy (EBRT) alone 
8  
Altered fractionation radiation therapy 
alone 
8  
Brachytherapy and conventionally 
fractionated EBRT 
5 
This procedure depends on size and 




Concurrent cetuximab and radiation 1  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
1  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
1  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
1  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
8 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT  9  
3-D multifield techniques 7  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 2: T1-2 N1-2a M0. 45-year-old man with no tobacco exposure history, 
HPV-positive. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 6  
Altered fractionation radiation therapy 
alone 
8  






Concurrent cetuximab and radiation 6  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
2  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
2  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
8 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT  9  
3-D multifield techniques 7  
If Concurrent Chemotherapy Is Given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 6  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 3: T1-2 N2b-3 M0. 45-year-old man with no tobacco exposure history, 
HPV-positive. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 2  
Altered fractionation radiation therapy 
alone 
5  






Concurrent cetuximab and radiation 6  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
5  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
3  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
7 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT  9  
3-D multifield techniques 7  
If Concurrent Chemotherapy Is Given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 6  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 4: T1-2 N1-2a M0. 65-year-old man with a 20 pack/year smoking history. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 3  
Altered fractionation radiation therapy 
alone 
7  






Concurrent cetuximab and radiation 6  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
2  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
2  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
7 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT 9  
3-D multifield techniques 5  
If Concurrent Chemotherapy is given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 6  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 5: T3-4 N0-2a M0. 65-year-old man. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 2  
Altered fractionation radiation therapy 
alone 
4 
This procedure is used if chemotherapy 
cannot be given. 






Concurrent cetuximab and radiation 6  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
5  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
4  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
6 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT 9  
3-D multifield techniques 4  
If Concurrent Chemotherapy Is Given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 6  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 6: T1-2 N2b-3 M0. 65-year-old man with a 20 pack/year smoking 
history. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 2  
Altered fractionation radiation therapy 
alone 
4 
This procedure is used if chemotherapy 
cannot be given. 






Concurrent cetuximab and radiation 6  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
5  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
4  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
7 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT 9  
3-D multifield techniques 7  
If Concurrent Chemotherapy Is Given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 6  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
Page 33 of 34
John Wiley & Sons, Inc.
Head & Neck










Clinical Condition: Local-Regional Therapy for Resectable Oropharyngeal Squamous 
Cell Carcinomas 
Variant 7: T3-4 N2b-3 M0. 45-year-old man. 
Treatment Rating Comments 
Conventional fractionated EBRT alone 2  
Altered fractionation radiation therapy 
alone 
3 
Consider this procedure if chemotherapy 
cannot be given. 






Concurrent cetuximab and radiation 5  
Induction chemotherapy followed by 
conventionally fractionated EBRT 
2  
Induction chemotherapy followed by 
concurrent platinum-based chemoradiation 
6  
Induction chemotherapy followed by 
concurrent cetuximab and radiation 
5  
Transoral or conventional surgical 
resection and neck dissection (if 
resectable) 
5 
This procedure is used with appropriate 
adjuvant therapy based on pathologic 
findings. 
Radiation Technique   
IMRT 9  
3-D multifield techniques 4  
If Concurrent Chemotherapy Is Given   
Cisplatin (100 mg/m
2
) × 2 to 3 cycles 8  
Cisplatin (75 mg/m
2
) × 3 cycles 6  
Cisplatin weekly (<30 mg/m
2
) 3  
Cisplatin weekly (≥30 mg/m
2
) 5  
Carboplatin/cisplatin and 5-FU 5  
Carboplatin and paclitaxel 5  
Cetuximab weekly 5  
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate 
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